Vol 8, No 3 (2022)
Research paper
Published online: 2022-09-30
Page views 907
Article views/downloads 25
Get Citation

Connect on Social Media

Connect on Social Media

Analysis of access to treatment of patients with moderate and severe psoriasis within nationally founded treatment program “Treatment of moderate and severe form of plaque psoriasis (ICD-10 L 40.0)” in 2016–2021

Marcin Noweta1, Joanna Narbutt1, Aleksandra Lesiak1
Forum Dermatologicum 2022;8(3):111-123.

Abstract

Introduction: Drug program B.47 “Treatment of moderate to severe form of plaque psoriasis (ICD-10 L 40.0)” has been operating since January 1, 2013. Since then, the description of the drug program has changed, and the funding and number of patients treated have increased as well. Material and methods: The publication uses data from NHF databases. The data for the years 2016–2021 were compiled and compared regarding the drug program B.47 “Treatment of moderate and severe plaque psoriasis (ICD-10 L 40.0)”. Results: In 2021, the drug program B.47 provided funding for 10 active substances: adalimumab, certolizumab, etanercept, guselkumab, infliximab, ixekizumab, risankizumab, sekukinumab, tildrakizumab, ustekinumab. In the last 6 years of the B.47 drug program, the number of patients has grown dynamically and In 2021, there were 2,156 patients. Most patients are treated in the drug program in Mazowieckie Voivodship, and the least in Podlaskie Voivodship. Over the years 2016–2021, the most patients were treated with adalimumab, and the least with tildrakizumab, which was reimbursed from the second half of 2021. At the end of 2021, the program was implemented in Poland in 34 centers. The B.47 program is one of the smaller in terms of funding. The value of contracts for drugs in this program constitutes only approximately 1% of the total funds allocated for financing drugs in drug programs. Conclusions: The number of patients treated in B.47 is relatively low compared to other programs and represents only 1% of all patients treated under drug programs. When analyzing the number of patients currently undergoing treatment, it should be noted that only about 0.3% of the population of patients with psoriasis is under the care of doctors under the drug program, which is a very low indicator compared to other European countries, but also to the number of patients in other countries. At the same time, almost all biological drugs registered for the treatment of patients with moderate and severe disease are financed from public funds. For several years, the description of the drug program has been undergoing changes aimed at optimizing patients’ access to effective treatment. Currently, dermatologists together with organizations of patients with psoriasis, postulate the introduction of changes regarding the abolition of the treatment time limit for all drugs in the drug program B.47, and the transfer of TNF alpha blockers to reimbursement on the open list.

Article available in PDF format

Add to basket: 49.00 PLN

Aready have access?

References

  1. Beers MH, Porter RS, Jones TV. he Merck manual – podręcznik diagnostyki I terapii. Wydanie 3 polskie. ELSEVIER Urban & Partner, Wrocław 2008: 1246–1253.
  2. NICE. Systemic biological therapy for psoriasis. NICE Pathway last updated: 02 March 2021. https://pathways.nice.org.uk/pathways/psoriasis/systemic-biological-therapy-for-psoriasis.pdf (14.06.2022).
  3. Reich A, Adamski Z, Chodorowska G, et al. Psoriasis. Diagnostic and therapeutic recommendations of the polish dermatological society. Part 2. Dermatology Review. 2020; 107(2): 110–137.
  4. Piekarska-Myślińska D, Pietrzak A, Myśliński W, et al. Łuszczyca wieku dziecięcego. Przegl Dermatol. 2017(104): 363–376.
  5. Obwieszczenie Ministra Zdrowia z dnia 21 grudnia 2012 r. w sprawie wykazu refundowanych leków, środków spożywczych specjalnego przeznaczenia żywieniowego oraz wyrobów medycznych na dzień 1 stycznia 2013 r.
  6. Zarządzenie nr 162/2020/DGL Prezesa Narodowego Funduszu Zdrowia z dnia 16 października 2020 r. w sprawie określenia warunków zawierania i realizacji umów w rodzaju leczenie szpitalne w zakresie programy lekowe.
  7. Informator o zawartych umowach. Informacja o zawartych umowach przez poszczególne Oddziały Wojewódzkie NFZ od 2008 roku. https://www.nfz.gov.pl/o-nfz/informator-o-zawartych-umowach/ (14.06.2022).
  8. Uchwała nr 3/2022/IV Rady Narodowego Funduszu Zdrowia z dnia 16 marca 2022 r. w sprawie przyjęcia okresowego sprawozdania z działalności narodowego funduszu zdrowia za IV kwartał 2021 r.
  9. Parisi R, Iskandar IYK, Kontopantelis E, et al. Global Psoriasis Atlas. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020; 369: m1590.
  10. Romańska-Gocka K. Farmakoterapia łuszczycy. Farm Pol. 2009; 65(9): 647–654.
  11. Elmets CA, Leonardi CL, Davis DMR. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities . J Am Acad Dermatol. 2019; 80(4): 1073–1113.
  12. EMA: Guideline on clinical investigation of medicinal products indicated for the treatment of psoriasis; CHMP/EWP/2454/02 corr. London, 2004). Data for coming into operations: June 2005. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-indicated-treatment-psoriasis_en.pdf (14.06.2022).
  13. Menter A, Strober B, Kaplan D, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol . 2019; 80(4): 1029–1072.
  14. Wielowieyska-Szybińska D, Wojas-Pe A. Wielowieyska – Szybińska D., Wojas – Pelc A. Przebieg i postępowanie w łuszczycy zwykłej. 2012; XXIX(2): 123–127.
  15. Psoriasis Treatment: Unmet Needs Present 2019 Opportunities. https://www.pm360online.com/psoriasis-treatment-unmet-needs-present-2019-opportunities/ (14.06.2022).
  16. Tłustochowicz W, Świerkot J, Stanisławska-Biernat E. Łuszczycowe zapalenie stawów. Zalecenia postępowania diagnostyczno-terapeutycznego, Reumatologia. ; 2016(supl. 1): 22–25.
  17. Obwieszczenie Ministra Zdrowia z dnia 20 kwietnia 2022 r. w sprawie wykazu refundowanych leków, środków spożywczych specjalnego przeznaczenia żywieniowego oraz wyrobów medycznych na 1 maja 2022 r.